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Abstract
Background: The PIM family kinases promote cancer cell survival and motility as well as metastatic growth in
various types of cancer. We have previously identified several PIM substrates, which support cancer cell migration
and invasiveness. However, none of them are known to regulate cellular movements by directly interacting with
the actin cytoskeleton. Here we have studied the phosphorylation-dependent effects of PIM1 on actin capping
proteins, which bind as heterodimers to the fast-growing actin filament ends and stabilize them.
Methods: Based on a phosphoproteomics screen for novel PIM substrates, we have used kinase assays and
fluorescence-based imaging techniques to validate actin capping proteins as PIM1 substrates and interaction
partners. We have analysed the functional consequences of capping protein phosphorylation on cell migration and
adhesion by using wound healing and real-time impedance-based assays. We have also investigated
phosphorylation-dependent effects on actin polymerization by analysing the protective role of capping protein
phosphomutants in actin disassembly assays.
Results: We have identified capping proteins CAPZA1 and CAPZB2 as PIM1 substrates, and shown that
phosphorylation of either of them leads to increased adhesion and migration of human prostate cancer cells.
Phosphorylation also reduces the ability of the capping proteins to protect polymerized actin from disassembly.
Conclusions: Our data suggest that PIM kinases are able to induce changes in actin dynamics to support cell
adhesion and movement. Thus, we have identified a novel mechanism through which PIM kinases enhance motility
and metastatic behaviour of cancer cells.
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Background
The hallmarks of malignant cancer cells that distinguish
them from healthy cells include increased motility and
an enhanced ability to invade other tissues and form
metastatic colonies [1]. Cellular movements are normally
strictly controlled by a network of intra- and extracellu-
lar components, which coordinate cell adhesion,
spreading, polarity and locomotion. These include
cadherin-like proteins that are responsible for adherent
cell-cell junctions, and transmembrane integrins that
connect the intracellular molecules to the extracellular
matrix [2, 3]. However, the main forces driving cell loco-
motion are dependent on actin dynamics: the constant
polymerization and depolymerization of actin filaments
[4]. This leads to changes in cellular protrusions such as
filopodia, lamellipodia as well as retraction fibers, which
are important mediators of both normal and cancer cell
movement [5].
Actin polymerization is regulated by several types of
actin-binding proteins, such as the capping proteins
(CPs) [5]. They bind as heterodimers to the fast-growing
ends of the actin filaments, and thereby prevent both
filament assembly and disassembly [6]. CP subunits are
evolutionarily conserved, but their number varies
between different species [7]. Originally, they were iden-
tified in the Z disks of striated muscles, but they have
since been found in other muscle and non-muscle
tissues as well [7–9]. CP alpha 1 and 2 subunits are
expressed in both types of tissues, while alpha 3 is a
germ cell-specific subunit [9–11]. Three different splice
variants have been identified for the beta subunit, of
which beta 1 is localized at the Z disks, and beta 2 at the
intercalated disks and cell periphery in the muscles [12].
The third variant, beta 3, is a testis-specific isoform simi-
lar to alpha 3 [13]. Despite their importance in skeletal
muscle, various functional roles have also been reported
in other tissues, such as cardiac tissue, the nervous
system and cancer [14–21].
The role of CPs in cancer has remained unclear due
to contradictory results with different subunits. While
the beta subunit has been reported to act as an onco-
gene, variable but mainly tumor suppressive roles have
been suggested for the alpha subunits [17–21]. These
opposite effects are surprising due to the heterodimeric
mode of CP action. However, as the previous data are
mostly based on silencing or overexpressing of individ-
ual subunits, they may not fully reflect the impact of
the heterodimers. It is also likely that CP activity is
context-dependent, as suggested by the differential
expression of their distinct subunits. In addition, CPs
are known to be targeted by post-translational modifi-
cations, such as phosphorylation by protein kinase Cε
and casein kinase 2, both of which reduce actin capping
activity [14, 22].
In this study, we have identified the CP alpha 1, alpha
2 and beta 2 subunits as novel substrates for the onco-
genic PIM1 kinase. The three serine/threonine-specific
PIM family kinases regulate cell growth, metabolism,
and motility, and have also neuronal functions [23–26].
They have been implicated in both hematopoietic malig-
nancies and solid cancers [23, 27, 28], and are therefore
promising targets for cancer therapy. The effects of PIM
kinases on cancer cell motility have been extensively
studied in prostate cancer, where they have been shown
to increase migration, invasion and adhesion of cultured
cells, and enhance tumor angiogenesis and metastasis in
vivo [29–32]. The pro-migratory effects of PIM kinases
have been connected to phosphorylation-dependent acti-
vation of several substrates such as NOTCH1, NFATC1
and EIF4B, or inactivation of tumor suppressive factors
such as FOXP3 [31, 33–36]. However, the previously
identified PIM substrates do not regulate cellular move-
ments by directly interacting with the actin cytoskeleton.
Here we have used a dual expression plasmid to simul-
taneously study the phosphorylation-dependent effects
of both CP alpha 1 and beta 2 subunits on prostate
cancer cell motility. We demonstrate that their
phosphorylation promotes adhesion and migration of
cultured cells, and also decreases their ability to protect
actin filament ends from disassembly in vitro. Thus, CP
phosphorylation is expected to increase actin dynamics
and thereby enhance the motility of prostate cancer
cells.
Methods
Cloning and mutagenesis
To create cDNA libraries, total mRNA was isolated with
Tri Reagent® (#T9424, Sigma-Aldrich, St Louis, MI,
USA) from mouse tissue or human PC-3 prostate cancer
cells, after which cDNA synthesis was performed using
the first strand cDNA synthesis kit (#K1612, Thermo
Fisher Scientific, Waltham, MA, USA). The cDNAs of
interest were subcloned into pGEM-T-Easy vector (Pro-
mega, Madison, WI, USA) by using PCR with gene-
specific primers. Further subclonings were performed ei-
ther by PCR or by digestion with restriction enzymes.
The gene-specific cloning and sequencing primers, and
the detailed design of constructs are shown in Add-
itional file 1: Tables S1 and S2.
For in vitro kinase assays with bacterially produced
proteins, mouse capza1 or human CAPZA2 cDNAs were
inserted together with mouse capzb2 cDNA into the
dual expression vector pRFSDuet-1 (shortened as
“Duet”, #71341, Merck Millipore, Burlington, MA, USA),
so that alpha subunits were placed into the multiple
cloning site (MCS) 1 and the beta subunit into MCS2.
The capzb2 cDNA was also subcloned into pGEX-6P-3
(GE Healthcare Life Sciences, Little Chalfont, UK).
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For expression in mammalian cells, His-tagged
capza1 and CAPZA2 constructs were prepared by
subcloning the cDNAs from Duet to the MCS1 of PSF-
CMV-CMV-SBFI-UB-PURO - DUAL CMV plasmid
(shortened as “Dual-CMV” or “Dual”; #OGS597, Sigma-
Aldrich, St. Louis, MI, USA). The capzb2 cDNA was
Flag-tagged by transferring it from pGEX-6P-3 to
pFlag-CMV™-2 (#E7033, Sigma-Aldrich), after which it
was further subcloned to Dual-CMV MCS2. For cre-
ation of GFP-tagged constructs, capzb2 was transferred
from pGEX-6P-3 to pEGFP-C1 (Clontech laboratories
Inc., Takara Bio USA, Inc., Mountain View, CA, USA).
In addition, GFP was subcloned from pEGFP-C1 into
Dual-CMV prior to MCS2 to create a GFP-tagged
Dual-CMV empty vector or a vector expressing Capza1
and GFP-tagged Capzb2.
Site-directed mutagenesis of mouse capza1 and capzb
genes was performed by Ultra Pfu DNA polymerase
(Stratagene, San Diego, CA, USA) according to Manu-
facturer’s protocol. The primers used are described in
Additional file 1: Table S3.
The short isoform of the murine Pim1 protein cap
away was expressed in bacterial cells from the pGEX-
2T-Pim1 vector as previously described [34]. The human
PIM1 protein was expressed in bacterial cells from the
pGEX-6P-1-PIM1 vector or in mammalian cells from
the pcDNA™3.1/PIM1-V5-His (from here on “pcDNA-
PIM1”) construct or Tag-PIM1-RFP (from here on
“PIM1-RFP”), which along with the GST-tagged murine
Notch1 intracellular domain (ICD) and the control plas-
mids have been described previously [33].
Protein production
For protein production, all bacterial constructs were
expressed in the BL21 E. coli strain. Production of
GST-tagged murine Pim1 or human PIM1 has been
described previously [34, 37]. For production of
heterodimers of Capza1 or CAPZA2 with Capzb2, cell
pellets were suspended in ice-cold lysis buffer (50 mM
Tris-HCl pH 7.5, 250 mM NaCl, 10 mM imidazole).
Protease activity was inhibited by aprotinin (1 μg/ml)
or PMSF (5 μM). Protein purification was performed
by rotating the lysate for 30 min at + 4 °C with 50%
HisLink™ resin (Promega). Thereafter samples were
washed four times in washing buffer (10 mM Tris-
HCl, pH 7.5, 20 mM imidazole) and rotated for 30 min
at + 4 °C with elution buffer (10 mM Tris-HCl, pH 7.5,
300 mM Imidazole, 250 mM NaCl). The His-tagged
alpha subunits formed heterodimers with the beta
subunits, so both subunits could be simultaneously
isolated. Protein samples were separated by SDS-
PAGE and visualised by Page Blue™ Protein Staining
Solution (Thermo Fisher Scientific).
PIM1 substrate screening, in vitro kinase assays and mass
spectrometry
Potential Pim1 substrates were identified using an
in vitro screen as previously described [38]. Briefly, rat
cortex was homogenized in kinase buffer and phosphor-
ylated in vitro at 30 °C for 45 min using recombinant
murine Pim1 kinase in the presence of [γ-32P] ATP
(PerkinElmer Finland Oy, Turku, Finland). Protein ex-
tract was loaded onto a dry polyacrylamide gel strip with
an immobilized pH gradient of 4–7, according to the
manufacturer’s instructions (Amersham Biosciences,
Uppsala, Sweden). Proteins were separated in the first
dimension by isoelectric focusing overnight at 3500 V,
followed by two-dimensional separation on 12% SDS-
PAGE, silver staining and autoradiography. Reduction,
alkylation, and in-gel trypsin digestion of the proteins
were performed as described previously [39]. Peptides
were extracted into 5% HCOOH, 50% CAN, concen-
trated using SpeedVac vacuum and desalted with
ZipTips with C18 resin (Millipore). After digestion,
peptides were mixed 1:1 with matrix α-ciane-4-hydroxy-
cinnamic acid (HCCA) dissolved in 70% ACN/0.1% TFA
and spotted onto a stainless steel target plate. Mass
spectrometry (MS) analysis was undertaken with a
MALDI-TOF/TOF Ultraflex II mass spectrometer
(Bruker Daltonics, Billerica, MA, USA). Spectra were in-
ternally calibrated with peptides from trypsin autolysis
(M +H+ = 842.509, M +H+ = 2211.104). The most abun-
dant peptide ions were then subjected to fragmentation
analysis (MS/MS) to provide information for use in de-
termining the peptide sequence. Data were processed by
Analyst QS software (Applied Biosystems, Foster City,
CA, USA) and matched to the SwissProt protein
database using the MASCOT algorithm.
Phosphorylation of putative substrates by human
PIM1 was validated by radioactive in vitro kinase assays,
as described previously [37]. Shortly, 0.5–2.0 μg of PIM1
and its substrate were used in each reaction. Samples
were separated by SDS-PAGE and stained by Page Blue™
protein staining solution (#24620, Thermo Fisher Scien-
tific). Results were analysed by autoradiography and
quantitated by the ChemiDoc™ MP Imaging System with
Image Lab software Version 4.0 (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) and ImageJ/Fiji software (1.48
s, Fiji, Wayne Rashband, National Institutes of Health,
Bethesda, MD, USA).
For mass spectrometry of phosphorylated substrates,
in vitro kinase assays were prepared similarly to the radio-
active assays, but without radiolabelled ATP. After SDS-
PAGE, the ProQ® Diamond Phosphoprotein Gel Stain
(Thermo Fisher Scientific) was used according to
manufacturer’s protocol. In-gel digestion of proteins with
trypsin, liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) with
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phosphopeptide enrichment and analysis of data have
been described previously [39–41]. Similar analyses were
performed also with immunoprecipitated cellular proteins.
In silico analyses for mRNA and proteins
Phosphorylation sites were searched for from the in vitro
kinase samples by the PhosphoMotif Finder in the Human
Protein Reference Database (http://www.hprd.org/Phos-
phoMotif_finder/). The in vivo phosphorylation sites were
searched for from the PhosphoSitePlus® database (phos-
phosite.org, Cell Signaling Technology, Inc., Danvers, MA,
USA). Gene expression data were obtained from the IST
Online™ (ist.medisapiens.com [42];) or betastasis database
(betastasis.com; gene expression barblot) [43]. Correlation
analyses were performed on gene expression data from
the betastasis dataset [43]. Homology comparisons were
performed by the Basic Local Alignment Search Tool
(National Institutes of Health, Bethesda, MD, USA) using
protein sequences from the National Center for Biotech-
nology Information (National Institutes of Health,
Bethesda, MD, USA) and UniProt Knowledgebase [44].
Cell culture and transfections
The human prostate epithelial adenocarcinoma cell line
PC-3 and the carcinoma cell lines DU-145 and LNCAP
(from American Type Culture Collection) were main-
tained in RPMI-1640 medium supplemented with 10%
fetal bovine serum, L-glutamine and antibiotics. For
transient transfections, cells were plated 24 or 48 h earl-
ier, cultured until ~ 80% confluence and then transfected
with the FuGENE® HD Transfection Reagent (Promega)
1:3 to DNA. Approximately 0.5 μg of DNA was used to
transfect 100,000 cells. The CP subunits were expressed
either by cotransfecting His-tagged Capza1 (Dual-CMV)
together with Flag-tagged Capzb2 (pFlag-CMV-2), or by
transfecting the Dual-CMV vector encoding both His-
tagged Capza1 or Capza2 and Flag-tagged Capzb2. The
Capzb2 subunit alone was expressed by the Flag-tagged
plasmid pFlag-CMV-2. To inhibit the catalytic activity of
PIM kinases, cells were treated with the PIM-selective
small molecule inhibitors DHPCC-9 [29, 45], AZD-1208
(Astra Zeneca, Cambridge, UK) or SGI-1776 (#526528,
Sigma-Aldrich) at 10 μM concentration in 0.1% DMSO,
which alone was used in control samples.
Nuclear fractionation
Cells cultured on 10 cm plates were lysed in 500 μl of
lysis buffer: 10 mM Tris-HCL pH 7.5, 10 mM NaCl, 3
mM MgCl2, 0.5% Nonidet P-40, 1 mM PMSF and mini
EDTA- free protease inhibitor tablet (Roche, Basel,
Switzerland) according to the manufacturer’s protocol.
100 μl of lysate was stored as a whole cell lysate control
and heated with 5x Laemmli sample buffer (LSB) for 5
min at + 95 °C. After centrifugation at 500 x g for 5 min
at + 4 °C, the supernatant contained the cytoplasm, while
the nuclei were in the pellet. The pellets were washed
three times with lysis buffer and centrifuged each time
at 500 x g for 5 min at + 4 °C, after which they were
suspended to 200 μl of lysis buffer. The cytoplasm-
containing solution was centrifuged at 12000 x g for 15
min at + 4 °C, after which the supernatant was collected.
Nuclear and cytoplasmic lysates were heated for 5 min
at + 95 °C with 5x LSB. 30 μl aliquots of samples were
loaded to each well on SDS-PAGE and samples were
analysed by Western blotting, using nuclear A/C laminin
and cytoplasmic beta-tubulin as fraction-specific positive
controls (Additional file 1: Table S4).
Western blotting
Cultured cells were directly lysed into 75–120 μl of hot
2x LSB or lysed for co-immunoprecipitation analyses as
described below. In both cases, LSB-containing samples
were heated for 5 min at 95 °C. Proteins (20–50 μl/ well)
were separated by 10–12% SDS-PAGE. After blotting
onto PVDF membrane, samples were stained with
primary antibodies (Additional file 1: Table S4) at + 4 °C
overnight. Secondary antibody staining (1:1000) was
performed for 30 min at RT with HRP-linked goat anti-
mouse IgG #7076 or goat anti-rabbit IgG #7074 anti-
bodies (Cell Signaling Technology, Beverly, MA, USA).
Immunoprecipitations and immunofluorescence
Cellular protein interactions were measured by co-
immunoprecipitation (CO-IP) and colocalization ana-
lyses, after which they were confirmed by proximity
ligation assays (PLA) and fluorescence-lifetime imaging
microscopy (FLIM). For IP and CO-IP, PC-3 cells were
cotransfected with pcDNA-PIM1, His-tagged Capza1
and Flag-tagged Capzb2. After 48 h, cells were scraped
into sterile PBS, centrifuged 300 x g for 3–4 min and re-
suspended into 5x volume of lysis buffer: 50 mM Tris
pH 7.5, 10% glycerol, 100 mM NaCl, 1 mM EDTA, 1%
NP-40, 50 mM NaF, 250 μM β-glycerophosphate, 1 mM
Na3VO4 and mini EDTA-free protease inhibitor tablet
(Roche) according to the manufacturer’s protocol. Sam-
ples were incubated on ice for 60 min, vortexed occa-
sionally and centrifuged for 10 min at 4 °C and 14,000
rpm. Supernatants were collected and protein concentra-
tions were measured using the Bio-Rad Protein Assay
Dye Reagent Concentrate (#5000006, Bio-Rad laborator-
ies Inc.) according to the manufacturer’s protocol. For
immunoprecipitation of Flag-tagged proteins, 0.5–1 mg
of protein lysate was combined with 50 μl of anti-Flag®
M2 affinity agarose gel (#A2220, Sigma-Aldrich) in 1ml
of lysis buffer. After 1 h rotation at + 4 °C, the agarose
gel was washed four times with the lysis buffer. Samples
were prepared by adding preheated 2x LSB, vortexing
and heating for 5 min at + 95 °C. Coprecipitated proteins
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and lysate controls (50–100 μg) were analysed by West-
ern blotting. For mass spectrometry, ~ 2.5 mg of protein
was used for immunoprecipitation, after which CP sub-
units were separated by SDS-PAGE and stained by Page
Blue.
For colocalization imaging, PLA and FLIM, PC-3 cells
were transiently co-transfected on coverslips or left
untransfected. After 24–48 h, samples were fixed at RT
for 15 min with 4% PFA. For colocalization, cells were
blocked in 10% BSA/PBS, followed by overnight incu-
bation with the primary antibodies (Additional file 1:
Table S4). On the following day, Alexa Fluor 488 goat
anti-mouse (#A11001) or Alexa Fluor 647 goat anti-
rabbit (#A21245) IgG secondary antibodies (Thermo
Fisher Scientific) were used 1:1000 for 1 h at RT.
During the secondary antibody staining, cells were sim-
ultaneously stained with DAPI (4′,6-diamidino-2-phe-
nylindole dihydrochloride, #D9542, Sigma-Aldrich, 300
nM) and/or Alexa Fluor™ 546 Phalloidin (#A22283,
Thermo Fisher Scientific, 150 nM) for visualization of
the nuclei and/or actin cytoskeleton. For PIM inhibitor-
treated, untransfected samples, Phalloidin–Atto 647 N
(#65906, Sigma Aldrich, 100 nM) was used to stain
actin filaments. Samples were imaged by the Zeiss LSM
780 confocal microscope with ZEN lite/Zen Black 2.3
software with 63x Zeiss C-Apochromat objective, nu-
merical aperture: 1.2 (Carl Zeiss, Oberkochen,
Germany) or the 3i CSU-W1 spinning disk confocal
microscope with SlideBook 6 software, 63x Zeiss Plan-
Apochromat objective, numerical aperture: 1.4 and Ha-
mamatsu sCMOS Orca Flash4 v2 C11440-22CU camera
(Intelligent, Imaging Innovations, Denver, CO, USA;
Hamamatsu Photonics, Hamamatsu City, Shizuoka
Pref., Japan). Colocalization was confirmed by Pearson’s
correlation coefficiency test and Costes Threshold re-
gression by ImageJ Coloc2 analysis. PLA was performed
according to the manufacturer’s protocol using the
Duolink® In Situ Orange Starter Kit Mouse/Rabbit
(DUO92102, Sigma-Aldrich). PLA samples were imaged
by the Nikon fluorescent microscope with NIS-
Elements AR software (Nikon, Tokyo, Japan). Samples
and figures were analysed and prepared using the re-
spective microscopy software and ImageJ/Fiji. Samples
for FLIM were directly mounted, while samples for the
other assays were permeabilized in 0.1–0.2% Triton-X-
100 for 15 min. FLIM was carried out as previously de-
scribed [31, 33] using the Lambert Instruments LIFA
FLIM system with the Carl Zeiss AxioImager micro-
scope and LI-FLIM software (Lambert Instruments BV,
Groningen, The Netherlands). All imaging was per-
formed at room temperature. Actin filament length and
number was manually measured in a double-blinded
fashion using ImageJ/Fiji and calculating protrusions
that were at least 3 μm long.
Cell motility, attachment and viability assays
Cell migration, cell adhesion and cell viability assays
were performed as described previously [29, 31]. For
wound healing assays to measure cell migration, wounds
were scratched by a 10 μl tip, after which they were
imaged by light microscopy with Basler Microscopy
Software 2.0 (Basler AG, Ahrensburg, Germany) and
analysed by ImageJ/Fiji. Single cell tracking was
performed at 37 °C, 5% CO2 by automated imaging with
the Nikon Eclipse Ti2-E microscope and NIS-Elements
AR 5.11.00 64-bit software with the 10x Nikon CFI
Plan-Fluor objective, numerical aperture: 0.3., and the
Hamamatsu sCMOS Orca Flash4.0 v3 C13440-20CU
camera. Cell movement was tracked manually by Ima-
geJ/Fiji from the .nd2 data files. Cell attachment was
studied using the electrical impedance-based Roche
xCelligence method with 15,000–25,000 cells plated per
well. Cell viability was measured by the MTT assay [29].
Western blotting samples were prepared after the exper-
iments to control for protein levels.
Actin disassembly assays
Actin polymerization and disassembly assays as well as
muscle actin production were performed as previously de-
scribed [46]. 10 μM non-labelled (95%) and pyrene-
labelled (5%) muscle actin were polymerized in a reaction
mix containing 1mM EGTA, 100mM NaCl, 5 mM
MgCl2. 0.2 mM ATP, 5mM Tris-HCl pH 7.5, 0.2 mM
DTT, 0.2mM CaCl2. The solution was gently mixed and
incubated first 15min at RT and then 40min at + 4 °C.
Thereafter the disassembly assay was performed at RT in
a reaction mix containing 1 mM EGTA, 100 mM NaCl, 5
mM MgCl2. 0.2 mM ATP, 5 mM Tris-HCl pH7.5, 1.2
mM DTT, 0.05 μM capping proteins produced in E. coli
or the elution buffer (a negative control) and 4 μM of po-
lymerized actin. The buffer and CPs were mixed gently by
rotating a pipette tip in the tube and incubating for 5min
at RT. Thereafter, 4 μM vitamin D-binding protein (Hu-
man DBP, G8764, Sigma-Aldrich) was added to sequester
actin monomers. Samples were carefully transferred into a
cuvette, after which the decrease in pyrene-actin signal
was measured by spectrophotometry (excitation 365 nm,
emission 407 nm) for 4000 s. Average signal intensities
were calculated by comparing each value to the first peak.
The START time-point represents an average of values of
100 s time scale after the first peak. Similarly, average
values from 100 s time scales were calculated for the other
time-points as well: 1000 s (900–1000 s average), 2000 s
(1900–2000 s average), 3000 s (2900–3000 s average) and
4000 s (3900–4000 s average).
Statistical analysis and figure preparation
The student’s t-test was used to compare the difference
between groups, while correlations were analysed by the
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Pearson’s correlation coefficiency. Significant differences
(P < 0.05) are marked with asterisks in figures and sup-
plementary files. Correlation coefficiencies (r [2]) were
interpreted as very weak (0.00–0.19), weak (0.20–0.39),
moderate (0.40–0.59), strong (0.60–0.79) or very strong
(0.80–1.00). Error bars represent standard deviations.
Corel Draw 2019 was used for figure preparation.
Results
Capping proteins are phosphorylated by PIM1 in prostate
cancer cells
The initial aim of our study was to identify novel neuronal
PIM substrates, as we have previously observed that pim
family mRNAs are prominently expressed in the central
nervous system [24] and that PIM kinases are active in
neuron-like cells [25]. For this purpose, we used an
in vitro phosphoproteomics-based method [38] and
recombinant mouse Pim1 kinase to screen for target
proteins from rat brain extracts. From this screen, we
identified five potential Pim1 substrates: capping protein
alpha 2 (Capza2), dihydropyrimidinase like 2 (Dpysl), eno-
lase 1 (Eno1), endocytosis-associated protein 1 (Necap1)
and prohibitin (Phb) (Additional file 2: Table S5). We next
decided to focus our validation efforts on the capping
protein (CP) family members, the phosphorylation of
which could potentially allow PIM kinases to directly
regulate actin dynamics and thereby cell motility.
To analyse phosphorylation of CP subunits by human
PIM1, radioactive in vitro kinase assays were performed
targeting human CAPZA2 or mouse Capza1 together
with mouse Capzb2. While these subunits had been
selected for the study based on their availability, no
species-specific differences were expected, as human and
murine CPs are highly homologous to each other (amino
acid identity for alpha 1 97%, alpha 2 98% and beta
2 100%) [44, 47]. The CPs were produced in bacteria as
heterodimers, and incubated with wild-type (WT) or
kinase-deficient (KD) human PIM1. As shown in Fig. 1a,
WT, but not KD PIM1 was able to phosphorylate
Capza1 and CAPZA2, although not as strongly as the
Notch1 intracellular domain (ICD) used as a positive
control. According to the relative signal intensities,
Capza1 subunit was more efficiently phosphorylated by
PIM1 than CAPZA2. Interestingly, however, Capzb2 was
phosphorylated only when it formed a heterodimer with
Capza1, but not with CAPZA2. These data validated the
Capza1/b2 heterodimer as a prominent direct target of
PIM1.
As we have previously shown that PIM kinases
promote PC-3 prostate cancer cell motility [29–31, 36],
we were interested in determining whether CPs are
involved in this process. We therefore searched for CP
mRNA expression levels from the IST Online™ database
[42], according to which relatively high levels of
CAPZA1 and CAPZB had been observed in PC-3 cells as
compared to CAPZA2 or CAPZA3 (Fig. 1b). For this
reason, as well as for the absence of in vitro phosphoryl-
ation of Capzb2 with CAPZA2, our further studies
focused on the functional consequences of phosphoryl-
ation of the Capza1/b2 heterodimer.
To evaluate whether CPs and PIM kinases are coex-
pressed in clinically relevant samples, we analysed the
PIM and CP mRNA expression levels in prostate tumors
of varying severity. According to data from the Betastasis
database [43], both CAPZA1 and CAPZB mRNA levels
positively correlated with PIM1 in primary prostate can-
cer patient samples (Fig. 1c-d). Positive correlations were
also detected in metastatic tissues as well as between dif-
ferent CP and PIM isoforms (Additional file 2: Table
S6). While CAPZA1, CAPZA2 and CAPZB, but not
CAPZA3 levels correlated well with PIM1 levels in all
tumor tissues, similar correlations were also observed
for PIM2 and PIM3 in the samples with high Gleason
scores. By contrast, no correlations were seen in healthy
prostate tissues. These data imply that PIMs and CPs
are both present in the cancer tissues, suggesting that
PIM-dependent phosphorylation of CPs can occur in
this setting.
Both CP subunits interact with and are phosphorylated
by PIM1
To identify the PIM1 target residues, Capza1 and
Capzb2 phosphorylation sites were analysed by mass
spectrometry from in vitro kinase assays as well as from
PC-3 cell co-immunoprecipitation assays. From those
samples, several in vitro and in vivo sites were detected
in both CP subunits (Fig. 1e, Additional file 2: Table S7).
In addition, in silico analysis [48] of the Capzb2 amino
acid sequence suggested that phosphorylation occurs at
S226. Mass spectrometry also identified phosphorylation
of Capzb2 at S2, but due to its close proximity to the N-
terminus of the protein, it was expected to be an artefact
and was not included in further studies. In addition,
Capzb2 was found to be phosphorylated at T186 in vivo,
but not in vitro, suggesting that it is targeted by a kinase
other than PIM1. To validate the phosphorylation sites,
the targeted serine residues were mutated to alanines
(SA) and tested by in vitro kinase assays. Mutagenesis of
the sites S106 and S126 in Capza1 and S182, S192 and
S226 in Capzb2 decreased the phosphorylation signal
efficiently and confirmed these sites as PIM1 target sites
(Fig. 1e).
To analyse the interactions between PIM1 and the CP
heterodimer, co-immunoprecipitation assays were per-
formed. For this purpose, PC-3 cells were transiently
transfected with different combinations of PIM1, Capza1
and Capzb2. When Flag-tagged Capzb2 was precipitated
with Flag agarose, both Capza1 and PIM1 were co-
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Fig. 1 (See legend on next page.)
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precipitated with it (Fig. 1f), indicating that PIM1 and
CPs physically interact with each other.
CP subunits colocalize with PIM1 in the cytoplasm
To obtain information on CP localization in PC-3 pros-
tate cancer cells, we analysed the subcellular distribution
of endogenously expressed CAPZA1, CAPZA2 and
CAPZB2 from fractionated cells by Western blotting. As
controls for the CP-specific antibodies, PC-3 cells were
transfected with His-tagged alpha subunits and Flag-
tagged beta subunit, while lamin A/C and tubulin
stainings were used as nuclear and cytoplasmic controls,
respectively. Interestingly, both CAPZA1 and CAPZB
proteins were mainly found from the cytoplasmic lysates,
while CAPZA2 was mostly nuclear (Additional file 3:
Fig. S1A-B).
Immunofluorescent stainings of transiently transfected
PC-3 cells confirmed that His-tagged Capza1 colocalizes
with Capzb2 in the cytoplasm (Additional file 3: Fig.
S2A). Colocalization of PIM1 with the CP heterodimer
was also observed in the cytoplasm at multiple positions
(Fig. 2a). Negative controls for primary and secondary
antibodies used in these assays are shown in the
Additional file 3: Fig. S2B. In addition, we analysed colo-
calization of PIM1 with either ectopically or endogen-
ously expressed alpha subunits. While in Western
blotting, the CAPZA1 and CAPZA2 antibodies detected
both subunits equally well (Additional file 3: Fig. S2C),
only the CAPZA2 antibody worked in the immunofluor-
escent stainings. However, most likely it was unable to
penetrate into the nuclei, as only cytoplasmic signals
were observed that most likely were derived from the
CAPZA1 subunit (Additional file 3: Fig. S2D).
Interactions between PIM1 and CPs were then ana-
lysed by proximity ligation assay (PLA), which confirmed
interactions between overexpressed Capza1, Capzb2 and
PIM1 (Fig. 2b), but revealed interactions also between
endogenously expressed proteins (Fig. 2c). Additional
controls for PLA assays with statistical analyses are
shown in Additional file 3: Fig. S3A-B.
Additional confirmatory data on cellular interactions
were obtained by fluorescence-lifetime imaging micros-
copy (FLIM). For that purpose, Capzb2 was N-
terminally tagged with GFP, and expressed either alone
or together with His-tagged Capza1. When these
plasmids were co-overexpressed in PC-3 cells with RFP-
tagged PIM1, the lifetime of GFP fluorescence was
reduced, indicating the presence of physical interactions
between PIM1 and Capzb2 (Additional file 3: Fig. S4A-
B). However, addition of the large fluorescent tag in-
creased the nuclear localization of Capzb2 (Additional
file 3: Fig. S4C-D), which is why the more cytoplasmic
Flag-tagged version of Capzb2 was chosen for further
functional assays.
CP phosphorylation promotes PC-3 prostate cancer cell
motility
As we have previously performed wound healing assays
to demonstrate the pro-migratory effects of PIM kinases
in PC-3 cells [29], we now wanted to analyse the role of
CP phosphorylation in this setting. For this purpose, we
used a dual expression vector to simultaneously overex-
press different combinations of wild-type (WT) and
phosphomutant forms of both CP subunits. For phos-
phodeficient mutants, PIM-targeted serine residues were
mutated to alanines (SA) and for phosphomimicking
mutants, they were mutated to glutamic acids (SE). From
here on, the SA or SE mutants are referred to with the
mutated residue number or with double (2X; S106 and
S126 in Capza1, or S182 and S192 in Capzb2) or triple
(3X; S182, S192, S226 in Capzb2) mutations. To facili-
tate interpretation of the results, the graphs have been
colour-coded: non-transfected or mock-transfected
samples (grey), wild-type CPs (black), Capza1 SA/SE
mutants (orange/yellow), Capzb2 SA/SE mutants (pur-
ple/blue), and combined Capza1/b2 SA/SE mutants
(dark green/light green).
In the wound healing assays, both wild-type CPs and
the phosphomimicking mutants promoted PC-3 cell mi-
gration as compared to controls or the phosphodeficient
(See figure on previous page.)
Fig. 1 CPs are phosphorylated by and co-expressed with PIM1 in prostate cancer. a Radioactive in vitro kinase assays were performed by
incubating human GST-tagged wild-type (WT) or kinase-deficient (KD) PIM1 with murine Notch1 intracellular domain (N1ICD, a positive control)
or with murine His-Capza1 or human His-CAPZA2 together with murine Capzb2. Shown are results from one representative experiment out of
three assays. Relative phosphorylation signal intensities as compared to loaded amounts of protein are shown under the blots. b CAPZ mRNA
levels expressed in human PC-3 prostate cancer cells were obtained from the IST Online™ database. c-d Pearson’s correlation coefficiencies were
determined to PIM and CAPZA1 or CAPZB mRNA levels in human prostate cancer patient samples obtained from the Betastasis database. Shown
are correlations (r2) along with significance (P) values. e Mass spectrometry (ms) of in vitro and in vivo phosphorylated CP samples as well as in
silico analysis were used to predict PIM kinase target sites. In vitro kinase assays were performed with GST-tagged PIM1 and either wild-type (WT)
CP or serine to alanine (SA) mutants, where two alpha sites (2X; S106, S126) or three beta sites (3X; S182, S192, S226) had been mutated. Shown
are representative figures with relative signal intensities. f Proteins interacting with Flag-Capzb2 were analysed from lysates of transiently
transfected PC-3 cells. Shown are examples of immunoprecipitation (IP), immunoblotting (IB) and and co-immunoprecipitation (CO-IP). Note that
the PIM1 antibody non-specifically detects also other proteins, most likely immunoglobulins
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mutants (Fig. 3a-b). In the case of the alpha subunit,
quite similar results were obtained after mutagenesis of
either one of the PIM target sites. The equivalent effects
of the double and triple mutants of Capzb2 indicated
that lack of the two identified in vivo sites was sufficient
to inhibit cell migration. Furthermore, the 2XSE mutant
of Capzb2 was sufficient to support wound healing also
in the absence of co-overexpressed Capza1, while the
2XSA mutant of Capzb2 alone reduced cell motility.
This implies that the ectopically expressed beta subunits
dimerize with the endogenous alpha subunits to regulate
cell movements. As the pan-PIM inhibitor DHPCC-9
Fig. 2 PIM1 interacts with the CP heterodimer in PC-3 prostate cancer cells. a PC-3 cells transiently overexpressing His-Capza1 and Flag-Capzb2
(CP) without or with PIM1 (P1) were stained for colocalization and b-c proximity ligation assays. DAPI staining was used in both assays to detect
the nuclei. Shown are representative images as well as Pearson’s correlation values (r2) of colocalized pixels and their Costes significance (P)
values. Scale bars represent 20 μm (a) or 25 μm (b-c)
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not only efficiently and selectively inhibits catalytic activ-
ities of all three PIM family kinases, but also slows down
PC-3 cell migration [29], we tested its effects in cells
transfected with Flag-tagged Capzb2. In the DMSO-
treated control samples, Capzb2 WT and 3XSE in-
creased cell motility in an expected fashion, while
Fig. 3 CP phosphorylation promotes PC-3 cell migration. a-b Wound healing assays were performed with PC-3 cells transiently overexpressing
Capza1/b2 wild-type (WT) proteins and/or phosphodeficient (SA) or phosphomimicking (SE), single, double (2X) or triple (3X) mutants. c Similar
assays were performed with cells that overexpressed only Capzb2 variants and were treated with DMSO (0.1%) or 10 μM PIM inhibitor DHPCC-9.
Shown are averages from at least three independent experiments with three parallel samples along with representative images. Wound edges
are lined in white. Scale bars represent 20 μm. Expression plasmid names are shown on top of the graph bars
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DHPCC-9 treatment resulted in significantly decreased
migration in all other samples except for the sample ex-
pressing the 3XSE mutant (Fig. 3c). Thus, the ability of
this phosphomimicking mutant to rescue the anti-
migratory effects of the PIM inhibitor strongly suggests
that phosphorylation of CPs is essential for PIM-induced
changes in cell motility.
To confirm that the above data were not due to differ-
ences in CP expression or cell viability, these parameters
were analysed. No major changes were detected in WT
versus mutant CP expression levels (Additional file 3:
Fig. S5A-D). However, the levels of Capzb2 SA or SE
mutants were reduced, when they were overexpressed
alone without Capza1 (Additional file 3: Fig. S5C). MTT
assays in turn showed that the CP mutants did not have
major effects on cell viability, while the PIM inhibitor
DHPCC-9 slightly decreased it in the transfected cells
(Additional file 3: Fig. S6A-C).
Phosphorylation of CPs regulates formation of actin
protrusions
As CPs regulate actin polymerization and have previ-
ously been reported to regulate actin protrusion forma-
tion at the cell edges [49], we wanted to measure the
effects of CP phosphorylation on the formation of actin
filopodia at the leading edge and retraction fibers at the
lagging edge. For this purpose, actin filaments were
stained by phalloidin and imaged in transiently
transfected PC-3 cells. Overexpression of the phospho-
deficient (3XSA) Capzb2 led to significantly increased
protrusion numbers, while the protrusions were also
slightly shorter than in the other samples (Fig. 4a-c,
Additional file 3: Fig. S7). We counted both leading edge
filopodia and lagging edge retraction fibers, provided
they were over 3 μm long. By contrast, both single
phosphomutants of Capza1 as well as the triple phos-
phomimicking (3XSE) mutant of Capzb2 slightly
reduced the protrusion number as compared to wild-
type, but did not affect their length.
When the effects of three structurally distinct PIM in-
hibitors (DHPCC-9, AZD-1208 and SGI-1776) were
compared by single cell tracking in wound healing as-
says, all inhibitors reduced PC-3 cell migration, but
DHPCC-9 was most efficient (Fig. 5a, b). Data from
MTT assays indicated that both DHPCC-9 and AZD-
1208 were well tolerated within the 24 h follow-up
period, whereas SGI-1776 showed significant cytotox-
icity (Fig. 5c). When DHPCC-9-treated cells were
stained with phalloidin, the number of actin protrusions
was dramatically increased, but without major effects on
their length (Fig. 5d-e). Altogether, these data suggest
that CP phosphorylation by PIM kinases restricts the
ability of cells to form actin protrusions at cell edges.
CP phosphorylation increases cell adhesion
We have previously observed that PIM inhibition by
DHPCC-9 inhibits cell adhesion to collagen and fibro-
nectin matrices [31]. To analyse the effects of CP phos-
phorylation on cell adhesion, we used xCelligence to
measure PC-3 cell attachment according to the electrical
impedance (resistance to alternating current). Cell adhe-
sion to collagen was slightly enhanced by overexpression
of WT Capza1 and Capzb2 (Fig. 6a), and was further
enhanced by the phosphomimicking mutants (9–24% in-
crease as compared to the wild-type protein), while the
phosphodeficient mutants had an opposite effect (8–16%
decrease as compared to the wild-type protein) (Fig. 6b-
c). By contrast, all cells adhered equally poorly to poly-
L-lysine, which was used as a negative control surface
(Additional file 3: Fig. S8A-C).
PIM-mediated CP phosphorylation increases actin
disassembly
To mechanistically analyse the effects of PIM-mediated
phosphorylation on CP actin capping activity, actin
disassembly assays were performed with or without
wild-type or mutant CPs. After actin polymerization, the
decrease in pyrene-labelled actin fluorescence was
followed up for more than an hour (4000 s). Vitamin D-
binding protein was added to prevent actin re-assembly,
as it has been shown to sequester actin monomers,
allowing us to follow actin depolymerization and CP
effects on the process [50, 51]. While actin by itself
slowly started to disassemble over time, wild-type CPs
prevented actin disassembly, but the phosphomimicking
mutants did not (Fig. 6d-e). Here it should be noted that
the bacterially produced wild-type protein was non-
phosphorylated, and was thereby expected to behave
similarly to the phosphodeficient mutant. These results
indicate that phosphorylation indeed interferes with the
actin capping activity.
Phosphorylation of CPs also promote the motility of DU-
145 prostate cancer cells
Finally, we wanted to compare the effects of PIM kinases
on the motility of other prostate cancer cell lines. For
this purpose, we used qPCR to measure relative PIM
mRNA levels in PC-3, DU-145 and LNCAP cell lines
(Additional file 3: Fig. S9A-C). PIM1 mRNA expression
was lower in LNCAP cells as compared to the others,
while no significant differences were detected in PIM2
and PIM3 mRNA levels between the cell lines. When we
performed wound healing assays, we found that DU-145
cells migrated faster than PC-3 cells, and that also their
motility could be reduced by a treatment with the
DHPCC-9 PIM inhibitor (Additional file 3: Fig. S9D-E).
By contrast, the migration rate of LNCAP cells was very
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low and not affected by PIM inhibition (Additional file
3: Fig. S9F).
When we compared CP expression in different pros-
tate cancer cell lines by Western blotting, we observed
slightly lower levels of CAPZA1 in PC-3 cells as com-
pared to the other lines, while CAPZB levels were high-
est in DU-145 cells (Additional file 3: Fig. S10A). To
analyse the role of CP phosphorylation in the rapidly mi-
grating DU-145 cells, wound healing assays were carried
out with cells that had been transiently transfected to
overexpress wild-type Capza1 with wild-type or mutant
Capzb2. No major changes were detected between the
expression levels of wild-type and phosphomutant pro-
teins (Additional file 3: Fig. S10B). Similarly to the data
from PIM inhibitor-treated cells, migration of DU-145
cells was affected by CP phosphorylation, but in a less
pronounced fashion (Additional file 3: Fig. S10C-D).
When adhesion of DU-145 cells was analysed, PIM in-
hibition by DHPCC-9 reduced adhesion to collagen in a
similar manner as observed in PC-3 cells (Additional file
3: Fig. S10E). Furthermore, transient overexpression of
wild-type Capzb2 or its phosphomimicking (3XSE) mu-
tant significantly promoted cell adhesion as compared to
control cells or those overexpressing the phosphodefi-
cient (3XSA) mutant (Additional file 3: Fig. S10F-G).
Data from MTT assays indicated that even though
DHPCC-9 slightly reduced viability of LNCAP cells, it
had no effects in DU-145 cells, the viability of which was
also only marginally affected by CP overexpression
(Additional file 3: Fig. S11A-C).
Fig. 4 CP dephosphorylation increases actin protrusion numbers at cell edges. a-c PC-3 cells plated on coverslips were transiently transfected to
overexpress wild-type (WT) Capza1 and Capzb2 or their phosphodeficient (SA) or phosphomimicking (SE) mutants. Actin filaments were stained
by phalloidin, and actin protrusion numbers and lengths were measured. Shown are averages from at least three individual samples along with
representative images for the Capzb2 phosphomutants. The increase in actin protrusion numbers in SA samples is pointed out by arrows. Scale
bars represent 10 μm
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Fig. 5 PIM inhibition increases the number of actin protrusions at cell edges. PC-3 cells were treated for 24 h with 10 μM DHPCC-9, AZD-1208 or
SGI-1776. Single cell tracking was performed to visualize the migration route and distance after PIM inhibition. a Shown are averages of indicated
numbers (n) of cells along with b representative images of cells treated with DMSO or DHPCC-9. Scale bars represent 20 μm. c MTT assays were
used to determine the relative viability of PC-3 cells after 24 h treatments with PIM inhibitors. Shown are averages from three independent
experiments with three parallel samples. d PC-3 cells were plated on coverslips and treated with DMSO or DHPCC-9 for 24 h, after which actin
filaments were stained by phalloidin, and the number of actin protrusions and their length were measured. Shown are averages of indicated
numbers (n) of cells along with e representative images for actin protrusions. Scale bars represent 10 μm. The increase in actin protrusion
numbers in DHPCC-9-treated samples is pointed out by arrows
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Discussion
The oncogenic PIM kinases support tumor growth as
well as cancer cell adhesion, migration, invasion and the
formation of metastases through multiple signalling
pathways [23]. Here we have identified capping proteins
as novel PIM substrates and demonstrate that PIM-
Fig. 6 CP phosphorylation increases cell adhesion and actin disassembly. a-c PC-3 cells were transiently transfected with wild-type (WT) Capza1
and Capzb2 or their phosphodeficient (SA) or phosphomimicking (SE) mutants. Cell adhesion to collagen was recorded according to the
electrical impedance. Similar experiments were performed at least three times with three parallel samples, while shown are representative results
from one experiment with three parallel samples. The statistical analyses were performed pairwise for each graph. d-e Actin polymerization was
performed by combining muscle actin with 5% pyrene-labelled actin. Thereafter actin disassembly was followed in vitro with or without addition
of bacterially produced CPs. Actin re-assembly was prevented by vitamin D-binding protein. Shown are average results from two to four
independent experiments with different combinations of samples. The statistical analyses were performed by comparing to the CP wild-type
control (Capza1-WT + Capzb2-WT)
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dependent phosphorylation of the CP heterodimers in-
hibits their actin capping activity and thereby enhances
actin dynamics and prostate cancer cell motility. To in-
vestigate the impact of phosphorylation, the CP subunits
or their phosphomimicking (SE) or phosphodeficient
(SA) mutants were simultaneously overexpressed using a
dual plasmid. To reduce potential off-target effects,
which have previously been associated with high expres-
sion levels [52, 53], all overexpression experiments were
initiated 12 h after transfection.
In our study, we observed that both subunits of the
Capza1/b2 heterodimer are phosphorylated by PIM1,
while in the other heterodimer formed by human
CAPZA2 and mouse Capzb2, only CAPZA2 was phos-
phorylated. This cannot be explained by species-specific
differences, as the beta subunits in mouse and human
are identical (Additional file 3: Fig. S12). Furthermore,
also the two alpha 1 phosphorylation sites and their sur-
rounding sequences are fully conserved between mouse
and human proteins (Additional file 3: Fig. S12). Based
on mRNA expression levels [42], the CAPZA1/B2
heterodimer is more prominently expressed than the
CAPZA2/B2 in the PC-3 prostate cancer cells, which
were used in most of our cellular assays. However, ac-
cording to our Western blotting data, both CAPZA1 and
CAPZA2 proteins are expressed in PC-3 cells, but have
distinct subcellular localizations. Alpha 1 is cytoplasmic,
but alpha 2 mostly nuclear, hinting at distinct functions
for the CAPZA1/B2 and CAPZA2/B2 heterodimers.
Based on our imaging and immunoprecipitation data,
PIM1 colocalizes and interacts with the CP heterodimer
mainly in the cytoplasmic regions, and promotes both
cell adhesion and migration in a phosphorylation-
dependent fashion. On the other hand, phosphorylation
of CAPZA2 was not studied in more detail and it may
therefore play an as of yet unknown role in the regula-
tion of e.g. nuclear actin dynamics in prostate cancer
cells.
Previously, capping protein activity has been reported
to be inhibited by multiple factors, while no activators
have been discovered. Proteins such as formins and Ena/
VASP proteins regulate CP function indirectly, while
myotrophin, phosphoinositides and CARMIL proteins
inhibit CPs directly by binding to them [6]. Very little is
known about post-translational modification of CPs, ex-
cept that Capza1 can be phosphorylated by the casein
kinase CK-2 at S9 [22], and CAPZB1 acetylated at K199
and phosphorylated by PKCε at S204 [14]. All these
modifications reduce capping activity. Here we have
shown that both CP alpha and beta subunits are
phosphorylated by PIM1: Capza1 at S106 and S126, and
Capzb2 at S182, S192 and S226. Phosphorylation
decreases the ability of CPs to protect actin filament
ends and thereby increases dynamical changes in actin
filament organization. This promotes the shortening or
elongation of filamentous actin. Here, in the phosphode-
ficient samples, the filament dynamics is blocked, and
increased numbers of slightly shortened filaments are
seen. The continuous changes in actin organization are
known to be needed for proper cell adhesion and migra-
tion [54]. As expected, we observed increases in both
cell adhesion and motility by overexpressing the
phosphomimicking mutants. The balance of CP activity
is expected to be crucial for proper actin dynamics and
cell shape formation. For instance, CP beta silencing has
been shown to increase the number of filopodia on cell
edges [49], while complete silencing or overexpressing
CPs leads to embryonic death [53].
All other PIM phosphorylation sites were identified
from cellular samples, except for S226 in Capzb2.
However, phosphorylation of this residue may be
context-dependent, as it has previously been observed to
be phosphorylated in colorectal cancer samples [48]. It
should also be noted that some of the PIM phosphoryl-
ation sites, as well as the additional T186 site of Capzb2,
may be targeted by other kinases as well. Furthermore,
the PIM consensus sequences (K/R-K/R-R-K/R-L-S/T-X
[55], K/R-K/R-K/R-X-S/T-X [56] and R-X-R-H-X-S
[57]) do not completely match with the CP target sites,
which is also the case with several other previously iden-
tified PIM kinase substrates [36, 58–61]. Therefore, it
may be worth re-evaluating the PIM1 consensus se-
quence in the future.
Our data may also have clinical implications. Here we
show positive correlations between PIM1 and either
CAPZA1, CAPZA2 or CAPZB mRNAs in prostate can-
cer samples with different Gleason grades, but not in the
healthy control tissues. Also, PIM2 and PIM3 mRNA ex-
pression levels correlate with those of CPs in more ad-
vanced tumors. Thus, the similar expression patterns of
PIM kinases and CPs at different cancer stages suggest
that their interactions may affect prostate cancer pro-
gression via phosphorylation-dependent regulation of
the capping activity. This is supported by our compara-
tive studies with additional prostate cancer cell lines.
Interestingly, the hormone-independent prostate cancer
cell lines PC-3 and DU-145 behave quite similarly, while
no major phosphorylation-dependent changes are de-
tected in the androgen-dependent LNCAP cells with
relatively low PIM1 levels. Thus, the higher PIM1 levels
and increased activity of PIM-mediated signalling path-
ways in PC-3 and DU-145 cells may be connected to
their increased motility as compared to LNCAP cells.
From a therapeutic perspective, it is crucial to know
the downstream targets of PIM kinases and to be able to
estimate the on- and off-target effects of PIM inhibitors.
According to our results, PIM inhibition is expected to
increase CP activity, resulting in decreased cancer cell
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migration. However, it would be important to analyse
the effects of PIM kinases and their inhibitors on other
CP subunits to confirm that PIM inhibition does not
cause any unexpected changes in healthy tissues, such as
muscle, testis or the nervous system, from where we
originally identified the Capza2 subunit as a neuronal
substrate for PIM1.
Conclusions
To summarize, CP alpha and beta subunits have previ-
ously been reported to behave in an opposite fashion
[17–21], leading to contradictory interpretations of the
role CPs play in cancer progression. Here we have dem-
onstrated that it is essential to simultaneously analyse
the effects of both CP subunits as a heterodimer, which
is the functional unit protecting the ends of actin fila-
ments. We have shown that phosphorylation of the
alpha 1 and beta 2 subunits by PIM1 reduces the actin
capping activity of the CP heterodimer, resulting in in-
creased prostate cancer cell motility. This is also the first
study linking PIM kinases directly to the regulation of
actin dynamics, highlighting the importance of PIM fam-
ily members in enhancing motility and metastatic behav-
iour of cancer cells.
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